Healthy Clinical Trial
Official title:
An Open, Dose Escalation Safety and Pharmacokinetics Study of the Medicine for Ebola Fever Emergency Prevention Based on Monoclonal Recombinant Antibodies With a Single Application in 3 Groups of Healthy Volunteers
This Phase I clinical trial was developed to study drug safety, tolerability, and pharmacokinetics of the medicine for Ebola fever emergency prevention based on monoclonal recombinant antibodies in single use in healthy volunteers with a dose escalation. A consecutive recruitment of people who signed the Informed Consent Form into three groups of volunteers with different drug doses is made according to the volunteers' screening results. The total number of volunteers receiving the drug will be not less then 25 people.The purpose of this study is to assess safety, tolerability, and pharmacokinetics of a medicine for Ebola fever emergency prevention based on monoclonal recombinant antibodies in a single dose in healthy volunteers.
The results of the screening of volunteers who signed the informed consent Form, is a
sequence set in three groups of volunteers with different doses of the drug, the total number
of volunteers who received the drug will be at least 25 people.
Taking into account the fact that for the first time the drug is studied on people, initially
five volunteers will be hospitalized. Their dose of the studied medicine will be 1.4 mg/kg of
weight. After confirmation of safety based on observation results on the 60th day of the
study, the investigation will continue with the participation of five more volunteers. Safety
will be studied on these five volunteers with a single use of dose of 7 mg/kg of weight.
After an intermediate safety assessment on the 60th day, 15 more volunteers will be included
in the study. They will get the medicine with the dose of 14 mg/kg of weight.
If necessary, understudies in an amount of not more than 4 people may be included. Volunteers
are replaced before the injection of the medicine. If a volunteer got the medicine, he could
not be replaced.
After evaluating the safety analyzes' intermediate results (blood test and blood chemistry,
urinalysis, immunological safety, clinical evaluation of general health status) obtained on
day 60 of the study, the Researcher, in agreement with the Ethics Committee, makes a decision
to include the second group (five people) to study the drug at a dosage of 7 mg/kg of weight.
After the evaluation of intermediate safety results on the 60th day of the study of
volunteers from the second group, 15 more volunteers will be included in the study. After the
intermediate evaluation of safety on the 60th day of study, 15 more volunteers will be
included in the study and get the medicine in a dose of 14 mg/kg of weight. Wherein the third
part of volunteers is planned to be included consistently: in the beginning 5 volunteers will
be included and after the intermediate safety evaluation on the 28th day the rest 10
volunteers will be included in the study.
The safety and tolerability assessment will be based on the registration of adverse events
during the study. Changes in instrumental (ECG) and laboratory indicators (blood test and
blood chemistry, blood coagulation system indicators, urinalysis, immunological status),
dynamics of vital signs (blood pressure, heart rate, body temperature) will be also
evaluated.
Pharmacokinetic parameters will be calculated by a model-independent method. Immunological
methods (ELISA) will be used for studying the level of specific antibodies and the duration
of their circulation in the human body.
Sampling of biological material involves:
Urinalysis: at screening, before administration of the drug after 48 hours and on 7, 10, 14,
21, 28, 45, 60 and 90 days of the study; urine samples for a pregnancy test taken at
screening and on the day of hospitalization (in addition to volunteers women).
to define security settings (General clinical and biochemical** blood tests, including a
study of the coagulation system): at screening, before dosing, 48 hours, and 7, 10, 14, 21,
28, 45, 60 and 90 days of the study; immune status***- the drug, 7, 10, 14, 21, 28, 45, 60
and 90 days of the study; will also be determining the level of specific antibodies to the
drug (with detection with the determination of class, subclass, immunoglobulins and
assessment of their functional activity) is the drug, 7, 10, 14, 21, 28, 45, 60 and 90 days
of the study; **biochemical blood analysis includes a determination of: total protein, urea,
creatinine, aspartataminotransferase (AST), alanine aminotransferase (ALT), alkaline
phosphatase, total bilirubin, glucose, cholesterol, creatine phosphokinase, CRP,
concentration of electrolytes (sodium, potassium), coagulation include: PI+, INR, APTT,
fibrinogen.
*** evaluation of the immunological status includes: determining the number and relative
content of subpopulations of T - and b-lymphocytes (CD3, CD 4, CD 8, CD 16, CD19), phagocytic
activity of white blood cells, immunoregulatory index, content of serum immunoglobulins major
classes (A, M, G, E), circulating immuno complexes, the detection of antibodies to the mouse
immunoglobulin, the content of anti-inflammatory cytokines (TNF-α, ИЛ1, IL-6, IFN-γ).
Blood samples for testing for hepatitis b and C, HIV and syphilis will be taken once at
screening visit.
In addition there will be samples of whole blood for analysis of pharmacokinetic parameters:
before drug administration, through 1, 4, 8, 24, 36, 48 and 96 hours after drug
administration, and 7, 10, 14, 21, 28, 45, 60 and 90 days study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |